- Home
- AORT vs PCRX Comparison
AORT vs PCRX Comparison
Compare AORT & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AORT
- PCRX
- Stock Information
- Founded
- AORT 1984
- PCRX 2006
- Country
- AORT United States
- PCRX United States
- Employees
- AORT N/A
- PCRX N/A
- Industry
- AORT Medical/Dental Instruments
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- AORT Health Care
- PCRX Health Care
- Exchange
- AORT Nasdaq
- PCRX Nasdaq
- Market Cap
- AORT 1.4B
- PCRX 1.2B
- IPO Year
- AORT 1993
- PCRX 2011
- Fundamental
- Price
- AORT $31.66
- PCRX $22.90
- Analyst Decision
- AORT Strong Buy
- PCRX Buy
- Analyst Count
- AORT 5
- PCRX 8
- Target Price
- AORT $32.40
- PCRX $28.38
- AVG Volume (30 Days)
- AORT 349.3K
- PCRX 545.0K
- Earning Date
- AORT 08-07-2025
- PCRX 07-29-2025
- Dividend Yield
- AORT N/A
- PCRX N/A
- EPS Growth
- AORT N/A
- PCRX N/A
- EPS
- AORT N/A
- PCRX N/A
- Revenue
- AORT $390,084,000.00
- PCRX $702,772,000.00
- Revenue This Year
- AORT $12.18
- PCRX $7.54
- Revenue Next Year
- AORT $10.39
- PCRX $10.78
- P/E Ratio
- AORT N/A
- PCRX N/A
- Revenue Growth
- AORT 5.94
- PCRX 3.08
- 52 Week Low
- AORT $21.97
- PCRX $11.16
- 52 Week High
- AORT $32.94
- PCRX $27.64
- Technical
- Relative Strength Index (RSI)
- AORT 62.03
- PCRX 35.82
- Support Level
- AORT $30.06
- PCRX $22.82
- Resistance Level
- AORT $32.94
- PCRX $23.83
- Average True Range (ATR)
- AORT 0.79
- PCRX 0.74
- MACD
- AORT 0.06
- PCRX -0.02
- Stochastic Oscillator
- AORT 61.37
- PCRX 6.22
About AORT Artivion Inc.
Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others. The company's has two reportable segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues. Company operates in North America, EMEA. LATAM, APAC. Maximum revenue is from North America.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.